NetraMark Holdings Inc. and the Centre for Addiction and Mental Health (CAMH) have received the prestigious Ontario Research Fund – Research Excellence (ORF-RE) Award for their innovative partnership aimed at advancing research in schizophrenia and major depressive disorders. The announcement was made on December 16, 2025, in Toronto, where CAMH is recognized as a leading institution in mental health research.
This collaboration will utilize NetraMark’s advanced AI platform, NetraAI, within CAMH’s secure computing environment to analyze genetic and epigenetic data from ongoing studies. The initiative seeks to identify patient subpopulations that clarify biological subtypes in psychiatric disorders, thereby supporting the development of next-generation precision treatment strategies.
Enhancing Clinical Outcomes Through Collaboration
The integration of NetraAI into CAMH’s research infrastructure is expected to enhance the capabilities of pharmaceutical sponsors by improving clinical trial outcomes. The installation process is being facilitated by CAMH’s Research IT team, with on-site support from NetraMark, ensuring compliance with data privacy and security standards.
Dr. James Kennedy, Head of the Tanenbaum Centre for Pharmacogenetics at CAMH, emphasized the significance of this collaboration: “This partnership allows us to explore how genetic and epigenetic patterns influence treatment responses. The insights we generate will enhance our understanding of the genetic factors that affect how patients respond to psychiatric medications, ultimately enabling more personalized treatment approaches.”
Dr. Joseph Geraci, Founder and Chief Scientific & Technology Officer of NetraMark, expressed pride in the recognition through the ORF-RE Award. He stated, “Combining CAMH’s extensive datasets with NetraAI’s unique explainable AI framework will help us uncover biologically relevant subpopulations that traditional analytics have missed. This collaboration is poised to contribute significantly to future precision medicine in mental health.”
Comprehensive Data Analysis for Health Impact
The project also involves the evaluation of an additional dataset from the Ontario Health Insurance Plan (OHIP) to perform cost-effectiveness analyses. This will help assess the broader impact of personalized patient care on the health system.
As Canada’s largest mental health and addiction teaching hospital, CAMH is committed to transforming the lives of individuals affected by mental illness and addiction. It combines clinical care, research, education, and health promotion to improve mental health outcomes. The partnership with NetraMark aligns with CAMH’s mission to leverage cutting-edge technology for impactful research.
NetraMark specializes in developing generative artificial intelligence and machine learning solutions tailored for the pharmaceutical industry. Its innovative approach enables the segmentation of patient data into manageable subsets, enhancing the accuracy of clinical trials and treatment efficacy assessments.
This collaboration marks a significant step forward in the intersection of AI and mental health research, paving the way for breakthroughs that could reshape treatment methodologies for complex psychiatric conditions.
